NVS up +0.55% percent Today $NVS High is at 94.49 and the Low 94.04 with current volume of 282,176.
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
How to Pick Stocks in the Wake of the Republican Election Victory
at The Street - 28 mins ago
From Keystone to pharmaceuticals, industrials and energy, the Republican wins in midterm elections create real opportunities investors can take advantage of.
PFE: 30.32 (-0.02), GSK: 45.93 (+0.19), CAT: 101.35 (+0.01), BA: 128.76 (-0.10), NVS: 94.61 (+0.66)
Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
CNW Group - Mon Nov 17, 7:00AM CST
Novartis presented first-time results of four pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor investigational secukinumab (AIN457) in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at the American College of Rheumatology (ACR) Annual Meeting, 14-19 November, in Boston, USA.
NVS: 94.61 (+0.66)
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
PR Newswire - Sun Nov 16, 1:37PM CST
Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) met primary endpoints demonstrating statistically significant improvement of the signs and symptoms of psoriatic arthritis (PsA) versus placebo. PsA is part of a spectrum of long-term diseases impacting joints, known as spondyloarthritis (SpA). There is a high unmet need for new treatment options for patients with PsA and approximately 45% of people are dissatisfied with their treatments. Secukinumab binds to and neutralizes interleukin-17A (IL-17A), which has been shown to play an important role in the development of inflammatory diseases. These results are being presented today at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 94.61 (+0.66)
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Thomson Reuters ONE - Sun Nov 16, 1:31PM CST
Novartis International AG / Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 94.61 (+0.66)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.40 (-0.45), LLY: 67.29 (-0.04), ABBV: 65.23 (+1.23), GSK: 45.93 (+0.19), SNY: 47.41 (+0.73), NVS: 94.61 (+0.66)
Forget Marijuana! This Is a Much Smarter Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 16, 11:11AM CST
Source: Flickr user Oswaldo. Although marijuana initiatives didn't log a perfect sweep in this year's midterm elections, the momentum behind the legalization movement remains intact. Two states (Oregon and Alaska), as well as Washington, D.C.,...
JNJ: 108.33 (+0.17), INSY: 38.36 (-0.21), GWPH: 75.53 (-0.10), GSK: 45.93 (+0.19), NVS: 94.61 (+0.66)
Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies
PR Newswire - Sat Nov 15, 3:50PM CST
Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS). In the studies, secukinumab met the primary endpoint demonstrating statistically significant improvements versus placebo in the signs and symptoms of AS. AS is a common type of spondyloarthritis (SpA), a spectrum of long-term inflammatory diseases impacting joints. Detailed study results will be presented during a plenary session (MEASURE 1) and in a poster presentation (MEASURE 2) at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 94.61 (+0.66)
Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Thomson Reuters ONE - Sat Nov 15, 3:45PM CST
Novartis International AG / Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 94.61 (+0.66)
Considering Foreign-Domiciled Dividend Growth Stocks
Dividend Mantra - Seeking Alpha - Fri Nov 14, 11:24PM CST
I was recently asked by a reader to discuss foreign stocks, dividend taxation, and how that applies to some of the stocks I discuss and invest in. The reader, who goes by wtd7576, commented in my recent article on Unilever PLC (NYSE: UL ) : ...
RDS.B: 72.40 (-0.21), TD: 50.82 (+0.23), BP: 40.80 (-0.14), SDRL: 20.74 (-0.04), UL: 40.69 (-0.02), VOD: 35.84 (+0.43), BNS: 61.17 (+0.29), BBL: 52.35 (-0.18), NVS: 94.61 (+0.66)
Diovan Case Study: How to Become a Leader in a Crowded Marketplace
PR Newswire - Fri Nov 14, 5:30PM CST
In 1997, Novartis launched its antihypertension treatment Diovan into a crowded marketplace. While the drug only banked a disappointing $80 million in sales in its first year, Diovan brand leaders convinced senior leadership to endorse a long-term strategy to build the brand's presence.
NVS: 94.61 (+0.66)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.38 (+0.33), REGN: 402.35 (+7.15), NVS: 94.61 (+0.66)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 87.10 (+1.39), ILMN: 182.00 (+1.50), QGEN: 23.53 (-0.03), NVS: 94.61 (+0.66)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.32 (-0.02), MRK: 59.65 (+0.58), BMY: 58.28 (+0.33), NVS: 94.61 (+0.66)
Tracking Tweedy Browne Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 13, 10:14AM CST
MMM: 158.96 (+0.11), KOF: 103.08 (+2.03), LMT: 186.36 (-0.24), DNOW: 28.50 (+0.16), WMT: 83.52 (+0.56), CNQ: 35.49 (-0.51), GOOG: 536.57 (-7.83), DEO: 118.23 (+0.54), BSBR: 5.42 (+0.01), NOV: 71.60 (+0.26), JNJ: 108.33 (+0.17), GOOGL: 546.71 (-8.48), BK: 39.74 (+0.07), UNP: 120.74 (+0.03), CSCO: 26.34 (+0.02), MA: 83.42 (-0.63), JOY: 52.96 (-0.30), TMK: 53.19 (-0.07), PSX: 72.70 (+0.92), DVN: 63.17 (-1.01), AXP: 90.09 (-0.58), UN: 39.28 (+0.13), EMR: 63.77 (+0.15), HAL: 49.68 (-5.40), COP: 70.94 (-0.47), WFC: 53.35 (unch), UL: 40.69 (-0.02), ITW: 93.62 (-0.16), PM: 87.17 (+0.89), TOT: 57.32 (+0.04), BAX: 71.94 (+0.19), ANAT: 113.45 (-0.85), BRK.B: 145.21 (-0.31), VZ: 51.39 (-0.11), CMCSA: 54.10 (unch), BRK.A: 217,834.48 (-188.52), NVS: 94.61 (+0.66)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.52 (+0.02), VVUS: 3.14 (-0.11), CSIQ: 26.19 (-0.74), KING: 16.23 (+0.11), NVS: 94.61 (+0.66)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 5.80 (-0.12), CLDX: 19.09 (+4.93), ATHX: 1.38 (+0.01), NVS: 94.61 (+0.66)
Ad Comm meeting approaches for Alcon intraocular lens
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:13PM CST
NVS: 94.61 (+0.66)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.82 (-0.04), NVS: 94.61 (+0.66)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.29 (+0.01), SJR: 26.86 (+0.04), PRGO: 154.96 (+0.50), XYL: 37.64 (+0.02), CHRW: 72.86 (-0.21), MDLZ: 38.18 (+0.02), MKC: 72.53 (-0.01), MDU: 25.05 (-0.04), SYY: 39.01 (+0.43), PDCO: 46.23 (+0.99), PNR: 69.02 (+0.36), TRI: 38.66 (+0.23), UPS: 106.48 (-0.35), PEP: 98.34 (+0.62), AGN: 209.55 (+10.90), MSI: 65.21 (-0.04), NOV: 71.60 (+0.26), NWN: 46.34 (+0.21), EGN: 65.87 (-2.09), EBAY: 54.89 (+0.53), QCOM: 70.64 (-0.21), AMAT: 22.49 (-0.33), ACN: 84.68 (+0.04), AAPL: 114.20 (+0.02), MA: 83.42 (-0.63), SCHW: 28.55 (-0.32), STR: 23.39 (+0.02), SE: 38.45 (+0.33), GAS: 52.06 (+0.61), IRM: 37.92 (+0.23), WM: 49.14 (+0.05), CMP: 88.92 (+0.09), VRSK: 63.04 (+0.17), GILD: 100.45 (-1.61), EXPD: 43.76 (-0.16), TFX: 115.77 (+0.94), CVS: 89.66 (+0.53), PG: 87.80 (-0.31), PX: 126.28 (+0.42), NVS: 94.61 (+0.66)
Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
PR Newswire - Wed Nov 12, 5:54AM CST
Malaria No More announced today that funding has been secured and an order has been placed for three million life-saving malaria treatments in advance of its three year, end of 2015 goal. The Power of One (Po1) campaign uses the latest social, mobile and e-commerce technologies to rally the global public in the fight against malaria. This is a major milestone for the organization and Po1 campaign partners Novartis (NYSE: NVS), the world's leading provider of malaria treatments; and Alere Inc. (NYSE: ALR), the world's leading provider of rapid diagnostic tests for infectious diseases, including malaria. To date, one million rapid diagnostic tests have been sent to Zambia through Po1.
ALR: 40.24 (+0.24), NVS: 94.61 (+0.66)
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
How to Pick Stocks in the Wake of the Republican Election Victory
at The Street - 28 mins ago
From Keystone to pharmaceuticals, industrials and energy, the Republican wins in midterm elections create real opportunities investors can take advantage of.
PFE: 30.32 (-0.02), GSK: 45.93 (+0.19), CAT: 101.35 (+0.01), BA: 128.76 (-0.10), NVS: 94.61 (+0.66)
Novartis presents results from four pivotal Phase III studies for investigational drug secukinumab (AIN457) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
CNW Group - Mon Nov 17, 7:00AM CST
Novartis presented first-time results of four pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor investigational secukinumab (AIN457) in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at the American College of Rheumatology (ACR) Annual Meeting, 14-19 November, in Boston, USA.
NVS: 94.61 (+0.66)
Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
PR Newswire - Sun Nov 16, 1:37PM CST
Novartis announced today results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) met primary endpoints demonstrating statistically significant improvement of the signs and symptoms of psoriatic arthritis (PsA) versus placebo. PsA is part of a spectrum of long-term diseases impacting joints, known as spondyloarthritis (SpA). There is a high unmet need for new treatment options for patients with PsA and approximately 45% of people are dissatisfied with their treatments. Secukinumab binds to and neutralizes interleukin-17A (IL-17A), which has been shown to play an important role in the development of inflammatory diseases. These results are being presented today at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 94.61 (+0.66)
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Thomson Reuters ONE - Sun Nov 16, 1:31PM CST
Novartis International AG / Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 94.61 (+0.66)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.40 (-0.45), LLY: 67.29 (-0.04), ABBV: 65.23 (+1.23), GSK: 45.93 (+0.19), SNY: 47.41 (+0.73), NVS: 94.61 (+0.66)
Forget Marijuana! This Is a Much Smarter Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 16, 11:11AM CST
Source: Flickr user Oswaldo. Although marijuana initiatives didn't log a perfect sweep in this year's midterm elections, the momentum behind the legalization movement remains intact. Two states (Oregon and Alaska), as well as Washington, D.C.,...
JNJ: 108.33 (+0.17), INSY: 38.36 (-0.21), GWPH: 75.53 (-0.10), GSK: 45.93 (+0.19), NVS: 94.61 (+0.66)
Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies
PR Newswire - Sat Nov 15, 3:50PM CST
Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS). In the studies, secukinumab met the primary endpoint demonstrating statistically significant improvements versus placebo in the signs and symptoms of AS. AS is a common type of spondyloarthritis (SpA), a spectrum of long-term inflammatory diseases impacting joints. Detailed study results will be presented during a plenary session (MEASURE 1) and in a poster presentation (MEASURE 2) at the American College of Rheumatology (ACR) Annual Meeting in Boston.
NVS: 94.61 (+0.66)
Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Thomson Reuters ONE - Sat Nov 15, 3:45PM CST
Novartis International AG / Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 94.61 (+0.66)
Considering Foreign-Domiciled Dividend Growth Stocks
Dividend Mantra - Seeking Alpha - Fri Nov 14, 11:24PM CST
I was recently asked by a reader to discuss foreign stocks, dividend taxation, and how that applies to some of the stocks I discuss and invest in. The reader, who goes by wtd7576, commented in my recent article on Unilever PLC (NYSE: UL ) : ...
RDS.B: 72.40 (-0.21), TD: 50.82 (+0.23), BP: 40.80 (-0.14), SDRL: 20.74 (-0.04), UL: 40.69 (-0.02), VOD: 35.84 (+0.43), BNS: 61.17 (+0.29), BBL: 52.35 (-0.18), NVS: 94.61 (+0.66)
Diovan Case Study: How to Become a Leader in a Crowded Marketplace
PR Newswire - Fri Nov 14, 5:30PM CST
In 1997, Novartis launched its antihypertension treatment Diovan into a crowded marketplace. While the drug only banked a disappointing $80 million in sales in its first year, Diovan brand leaders convinced senior leadership to endorse a long-term strategy to build the brand's presence.
NVS: 94.61 (+0.66)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.38 (+0.33), REGN: 402.35 (+7.15), NVS: 94.61 (+0.66)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 87.10 (+1.39), ILMN: 182.00 (+1.50), QGEN: 23.53 (-0.03), NVS: 94.61 (+0.66)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.32 (-0.02), MRK: 59.65 (+0.58), BMY: 58.28 (+0.33), NVS: 94.61 (+0.66)
Tracking Tweedy Browne Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 13, 10:14AM CST
MMM: 158.96 (+0.11), KOF: 103.08 (+2.03), LMT: 186.36 (-0.24), DNOW: 28.50 (+0.16), WMT: 83.52 (+0.56), CNQ: 35.49 (-0.51), GOOG: 536.57 (-7.83), DEO: 118.23 (+0.54), BSBR: 5.42 (+0.01), NOV: 71.60 (+0.26), JNJ: 108.33 (+0.17), GOOGL: 546.71 (-8.48), BK: 39.74 (+0.07), UNP: 120.74 (+0.03), CSCO: 26.34 (+0.02), MA: 83.42 (-0.63), JOY: 52.96 (-0.30), TMK: 53.19 (-0.07), PSX: 72.70 (+0.92), DVN: 63.17 (-1.01), AXP: 90.09 (-0.58), UN: 39.28 (+0.13), EMR: 63.77 (+0.15), HAL: 49.68 (-5.40), COP: 70.94 (-0.47), WFC: 53.35 (unch), UL: 40.69 (-0.02), ITW: 93.62 (-0.16), PM: 87.17 (+0.89), TOT: 57.32 (+0.04), BAX: 71.94 (+0.19), ANAT: 113.45 (-0.85), BRK.B: 145.21 (-0.31), VZ: 51.39 (-0.11), CMCSA: 54.10 (unch), BRK.A: 217,834.48 (-188.52), NVS: 94.61 (+0.66)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.52 (+0.02), VVUS: 3.14 (-0.11), CSIQ: 26.19 (-0.74), KING: 16.23 (+0.11), NVS: 94.61 (+0.66)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 5.80 (-0.12), CLDX: 19.09 (+4.93), ATHX: 1.38 (+0.01), NVS: 94.61 (+0.66)
Ad Comm meeting approaches for Alcon intraocular lens
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:13PM CST
NVS: 94.61 (+0.66)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.82 (-0.04), NVS: 94.61 (+0.66)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.29 (+0.01), SJR: 26.86 (+0.04), PRGO: 154.96 (+0.50), XYL: 37.64 (+0.02), CHRW: 72.86 (-0.21), MDLZ: 38.18 (+0.02), MKC: 72.53 (-0.01), MDU: 25.05 (-0.04), SYY: 39.01 (+0.43), PDCO: 46.23 (+0.99), PNR: 69.02 (+0.36), TRI: 38.66 (+0.23), UPS: 106.48 (-0.35), PEP: 98.34 (+0.62), AGN: 209.55 (+10.90), MSI: 65.21 (-0.04), NOV: 71.60 (+0.26), NWN: 46.34 (+0.21), EGN: 65.87 (-2.09), EBAY: 54.89 (+0.53), QCOM: 70.64 (-0.21), AMAT: 22.49 (-0.33), ACN: 84.68 (+0.04), AAPL: 114.20 (+0.02), MA: 83.42 (-0.63), SCHW: 28.55 (-0.32), STR: 23.39 (+0.02), SE: 38.45 (+0.33), GAS: 52.06 (+0.61), IRM: 37.92 (+0.23), WM: 49.14 (+0.05), CMP: 88.92 (+0.09), VRSK: 63.04 (+0.17), GILD: 100.45 (-1.61), EXPD: 43.76 (-0.16), TFX: 115.77 (+0.94), CVS: 89.66 (+0.53), PG: 87.80 (-0.31), PX: 126.28 (+0.42), NVS: 94.61 (+0.66)
Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
PR Newswire - Wed Nov 12, 5:54AM CST
Malaria No More announced today that funding has been secured and an order has been placed for three million life-saving malaria treatments in advance of its three year, end of 2015 goal. The Power of One (Po1) campaign uses the latest social, mobile and e-commerce technologies to rally the global public in the fight against malaria. This is a major milestone for the organization and Po1 campaign partners Novartis (NYSE: NVS), the world's leading provider of malaria treatments; and Alere Inc. (NYSE: ALR), the world's leading provider of rapid diagnostic tests for infectious diseases, including malaria. To date, one million rapid diagnostic tests have been sent to Zambia through Po1.
ALR: 40.24 (+0.24), NVS: 94.61 (+0.66)
